Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yaolin Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0971-518X; OpenAlex author ID A5043588779. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 7 papers

Papers 16

  1. The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer. Co-author DOI 10.1002/advs.202500806↗
  2. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
  3. Pancreatic surgery is safe in elderly patients with PDAC. Co-author DOI 10.1186/s12877-025-05907-8↗
  4. Contrast-enhanced MRI-based intratumoral heterogeneity assessment for predicting lymph node metastasis in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13244-025-01956-0↗
  5. Correction: Contrast-enhanced MRI-based intratumoral heterogeneity assessment for predicting lymph node metastasis in resectable pancreatic ductal adenocarcino… Co-author DOI 10.1186/s13244-025-01973-z↗
  6. MRI-based risk stratification for predicting overall survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13244-025-02088-1↗
  7. Deciphering molecular crosstalk mechanisms between skeletal muscle atrophy and KRAS-mutant pancreatic cancer: a literature review. Co-author DOI 10.21037/hbsn-24-282↗
  8. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  9. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection ma… First author DOI 10.3389/fonc.2023.1109068↗
  10. Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis. Co-author DOI 10.3389/fonc.2022.789351↗
  11. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. First author DOI 10.1007/s10147-020-01782-y↗
  12. Upregulated circRNA hsa_circ_0071036 promotes tumourigenesis of pancreatic cancer by sponging miR-489 and predicts unfavorable characteristics and prognosis. Co-author DOI 10.1080/15384101.2021.1874684↗
  13. Positive Impact of Intraoperative Epidural Ropivacaine Infusion on Oncologic Outcomes in Pancreatic Cancer Patients Undergoing Pancreatectomy: A Retrospective … First author DOI 10.7150/jca.57661↗
  14. Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection. Co-author DOI 10.1093/jjco/hyaa035↗
  15. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyy063↗
  16. miR-1247 is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins. Co-author DOI 10.2174/1566524014666140228120014↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenchuan Wu · 8 shared papers, 2018–2025 · strength 1.32
  2. Dansong Wang · 8 shared papers, 2018–2025 · strength 1.29
  3. Wenhui Lou · 6 shared papers, 2020–2025 · strength 0.98
  4. Yueming Zhang · 5 shared papers, 2020–2025 · strength 0.84
  5. Wenhui Lou · 4 shared papers, 2022–2025 · strength 0.70
  6. Zongyu Xie · 3 shared papers, 2025 · strength 0.66
  7. Tiantao Kuang · 4 shared papers, 2020–2024 · strength 0.58
  8. Xuefeng Xu · 3 shared papers, 2021–2024 · strength 0.45
  9. Dayong Jin · 3 shared papers, 2021–2024 · strength 0.45
  10. Junjian Shen · 2 shared papers, 2025 · strength 0.45
  11. Jianjun Zhou · 2 shared papers, 2025 · strength 0.45
  12. Haitao Sun · 2 shared papers, 2025 · strength 0.45
  13. Zhihang Xu · 2 shared papers, 2025 · strength 0.41
  14. Ning Pu · 2 shared papers, 2025 · strength 0.41
  15. Jiande Han · 2 shared papers, 2025 · strength 0.41
  16. Hanlin Yin · 2 shared papers, 2025 · strength 0.41
  17. Haibo Wang · 2 shared papers, 2025 · strength 0.41
  18. Qiangda Chen · 2 shared papers, 2025 · strength 0.41
  19. Jun Yu · 2 shared papers, 2025 · strength 0.41
  20. Taochen He · 2 shared papers, 2025 · strength 0.41
  21. Yun Jin · 2 shared papers, 2025 · strength 0.41
  22. Liang Liu · 2 shared papers, 2024–2025 · strength 0.40
  23. Xi Guo · 3 shared papers, 2018–2024 · strength 0.40
  24. Lili Wu · 3 shared papers, 2018–2024 · strength 0.40
  25. Wenquan Wang · 2 shared papers, 2024–2025 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.